Montelukast to reduce inflammation and heart damage after a heart attack
Official title: Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction: A Randomized Controlled Trial
Run by October 6 University · NCT07537868 · Data updated 2026-11-12
This trial will try montelukast versus placebo to see if it lowers inflammation and limits heart muscle injury in adults aged 30–75 who have a STEMI treated within 6 hours with PCI or thrombolysis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 30 Years to 75 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | October 6 University Academic / other |
| Locations | 1 site (Al Mansurah) |
| Status | Recruiting |
| Started | April 20, 2026 |
| Main results expected | May 2027 |
| Study ends | October 2027 |
| Registry record updated | May 8, 2026 |
| Trial ID | NCT07537868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 30–75 years old with a confirmed STEMI presenting within 6 hours who are undergoing PCI or thrombolysis and can provide informed consent.
✕Probably not a fit
Patients with chronic anti-inflammatory use, severe liver or kidney disease, autoimmune or inflammatory disorders, cardiogenic shock or severe heart failure, prior myocardial infarction, active bleeding, recent major GI surgery, pregnancy or lactation, known montelukast hypersensitivity, psychiatric risk, or current participation in another trial are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, two-arm, placebo-controlled Phase 2 trial enrolls adults with acute ST-elevation myocardial infarction who present within 6 hours and receive PCI or thrombolysis. Participants are randomly assigned to montelukast 10 mg orally or matching placebo in addition to standard acute coronary syndrome therapy, with blood and clinical data collected. The study measures changes in inflammatory markers and the extent of cardiac injury using biomarkers and clinical/imaging assessments during the acute recovery period. The trial is led by October 6 University in collaboration with Mansoura University and is conducted at Mansoura Faculty of Medicine hospital in Al Mansurah, Egypt.
Why it matters
Potential benefit: If successful, montelukast could reduce post-heart-attack inflammation and limit heart muscle damage, potentially improving short- and long-term recovery.
How similar studies have gone: Preclinical data and a few small clinical reports suggest leukotriene blockade may reduce post-MI inflammation, but randomized clinical evidence in acute MI is limited, so this is a relatively novel repurposing approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 30-75 years Diagnosed with STEMI within 6 hours of symptom onset Undergoing PCI or thrombolysis Eligible for standard ACS therapy signed Informed consent Exclusion Criteria: * Chronic use of anti-inflammatory drugs * Severe hepatic or renal impairment * Hypersensitivity to Montelukast * Autoimmune or inflammatory diseases * Cardiogenic shock, severe heart failure or structural complications such as papillary muscle rupture * Having received cardiopulmonary resuscitation * Severe and inadequately controlled hypertension * History of myocardial infarction * Concomitant active bleeding or visceral hemorrhage * Concomitant malignant tumors, lymphomas, leukemias, or other diseases * gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug * Family history of psychiatric disorders * Pregnancy or lactation * Participation in another clinical trial
Where it's running
-
Mansoura Faculty of Medicine hospital
Al Mansurah, Egypt Recruiting
Study contacts
- Study coordinator: Abdallah Alshammari, MD
- Email: Phd.abdulla7@gmail.com
- Phone: 06500556855
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can 1-Hz rTMS help with heart rhythm and inflammation after a heart attack?
This trial tests whether daily 1-Hz repetitive transcranial magnetic stimulation can improve heart rate variability and reduce inflammation in people who have had an acute myocardial infarction, compared with a sham procedure.
-
Trends and risk factors for adverse events after primary PCI in AMI patients over 20 years
This study looks at real-world AMI patients who had a primary PCI to see how often serious events happen during a 2-year follow-up and what factors predict them.
-
SPIKE FLOW endocardial pacing lead safety and performance study
This study tests whether the SPIKE FLOW temporary endocardial pacing lead is safe and effective in adults needing temporary pacing during heart-related conditions.
-
Predict Arrhythmia Risk with Intelligent Software
Researchers are testing AI-powered predictions to see if clinicians can spot patients at risk for dangerous heart rhythms using bedside ECG data.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
BRIDGE: Embedding consumer mHealth tools into cardiac rehab
This study tests whether adding a mobile health tool to standard center-based cardiac rehab helps heart patients stay active and follow healthy habits.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.